| Name | Title | Contact Details |
|---|
Comprehensive Practice Management Services is a Lincoln, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Helping Hands Family is a group of ABA therapy clinics in PA, NJ, NY, MD, & CT that provides personalized Applied Behavior Analysis (ABA) therapy to help children with autism socialize, learn, and grow.
Ascendis Pharma is focused on creating drug candidates that are improved versions of existing drugs, yielding more effective, lower-risk drugs with new patent life. Our proprietary TransCon platform is the leading, most versatile transient conjugation technology and is utilized to create clinically superior prodrugs in therapeutic areas characterized by high unmet medical need. TransCon technology creates novel long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. Ascendis Pharma has a diversified and balanced high-value pipeline, including internal programs and partnerships together with market leaders on their key projects.
ACS EDI Gateway is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.